Studies completed in the mouse NASH model showed GR-MD-02 reduced or eliminated fibrosis as measured by liver collagen content, and reduced the expression of galectin-3 in liver macrophages [6]. This evidence concerns the gene LGALS3 and metabolic dysfunction-associated steatohepatitis.